Compare Abeona Therapeutics Inc (ABEO) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Teucrium Corn Fund — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Teucrium Corn Fund trades at $17.39. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | CORN | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $19.12 |
52-Week Low | $4.17 | $16.46 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CORN stock trades at $17.45, up 3.5% today, with a bullish technical signal from moving averages and oscillators. Key support is at $17 and resistance at $18. Recent news includes a licensing partnership with Hormel Foods for CORN NUTS® brands (GlobeNewsWire, 2026-05-07).
The outlook is cautiously optimistic given technical momentum, but fundamental data is unavailable. Risks include reliance on brand licensing and broader market volatility. Investors should monitor upcoming earnings for financial health indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
